New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
–Patients tolerated as much as 2,000 mg of peanut protein with fewer adverse events — –Favorable ongoing and notable immunological…